Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis

Rentka, Anikó; Hársfalvi, Jolán; Szűcs, Gabriella; Szekanecz, Zoltán; Szodoray, Péter; Köröskényi, Krisztina; Kemény-Beke, Ádám

doi:10.1007/s12026-015-8763-9

Cited by 14 publications

(12 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This screening method was performed for the assortment of 102 cytokines, selecting the most relevant ones in the pathogenesis of SSc for further experiments. All molecules which appeared to be significantly higher in tears of patients are molecular players of the immune responses and inflammatory processes, which confirms the presence of ocular surface inflammation in patients with SSc possibly as a consequence of DES [36].…”

Section: Membrane Array and Multiplex Bead Analysis Of Tear Cytokinessupporting

confidence: 65%

“…This may indicate that total protein production-or simply protein concentration, since patients with SSc have a decreased tear secretion velocity-is only increased because of the smaller tear volume. VEGF in the tears of patients with SSc decreased by 20%, which can be explained also by the decreased tear secretion of patients [36].…”

Section: Vegf In Tear Samples Of Patients With Sscmentioning

confidence: 93%

“…They calculated the average tear fluid secretion in healthy controls, which was 8.1 μl/min (0.7-20.8), using the same tear collecting method as we did in our study. Results show that patients with SSc have significantly decreased tear secretion that could be explained by DES, which is a probable sequel of the disease or to the side effects of the therapeutic drugs [36].…”

Section: Vegf In Tear Samples Of Patients With Sscmentioning

confidence: 95%

“…Monitoring these factors in the tears of patients with SSc can be a noninvasive alternative to serum investigation. Additionally, in patients with ocular manifestations, such as DES, tear analysis is far more informative; it provides information of the ocular surface; hence it could help us choose the appropriate treatment, in particular artificial tears or anti-inflammatory eye drops [36]. Further studies are needed to understand the signaling pathways regulating pro-inflammatory cytokines, with the aim of developing new interventions against autoimmune diseases mediated by cytokines and chemokines, as well as inventing novel therapeutic possibilities for the ocular manifestations of SSc.…”

Section: Future Plansmentioning

confidence: 99%

“…Parts of this chapter are reproduced from authors' recent work mentioned in the "Reference" section and properly cited in the body of the chapter (Refs. [34,36]). Permission from authors/ publishers for the usage of the content of their articles has been obtained.…”

Section: Acknowledgementsmentioning

confidence: 99%

See 4 more Smart Citations

Ophthalmological Manifestations and Tear Investigations in Systemic Sclerosis

Rentka¹,

Köröskényi²,

Hársfalvi³

et al. 2017

Systemic Sclerosis

Self Cite

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by widespread small vessel vasculopathy, immune dysregulation with production of autoantibodies, and progressive fibrosis. There are only few reports available concerning ophthalmological complications in the course of SSc, although ocular manifestations, e.g., dry eye syndrome (DES), occurs frequently and decreases the quality of life of these patients. Vascular endothelial growth factor (VEGF), the major pro-angiogenic factor, plays a key role in the pathomechanism of SSc. Although elevated levels of VEGF in sera have already been demonstrated, VEGF analysis in tears of patients with SSc has not been performed in previous studies. VEGF in the tears of patients with SSc was found to be decreased by 20%, compared to healthy controls. The reason why the VEGF levels are not elevated in the tears of patients with SSc needs further investigations, as does the sera of the same patients. The cytokine array results revealed a shift in the cytokine profile characterized by the predominance of inflammatory mediators. Our current data depict a group of cytokines and chemokines, which play a significant role in ocular pathology of SSc; furthermore, they might function as excellent candidates for future therapeutic targets in SSc with ocular manifestations.

show abstract

Section: Membrane Array and Multiplex Bead Analysis Of Tear Cytokinessupporting

confidence: 65%

Section: Vegf In Tear Samples Of Patients With Sscmentioning

confidence: 93%

Section: Vegf In Tear Samples Of Patients With Sscmentioning

confidence: 95%

Section: Future Plansmentioning

confidence: 99%

Section: Acknowledgementsmentioning

confidence: 99%

See 3 more Smart Citations

Ophthalmological Manifestations and Tear Investigations in Systemic Sclerosis

Rentka¹,

Köröskényi²,

Hársfalvi³

et al. 2017

Systemic Sclerosis

Self Cite

View full text Add to dashboard Cite

show abstract

Contact Lens Technology: From Fundamentals to Applications

Moreddu

Vigolo

Yetisen

2019

Adv Healthcare Materials

190

171

View full text Add to dashboard Cite

Contact lenses are ocular prosthetic devices used by over 150 million people worldwide. Primary applications of contact lenses include vision correction, therapeutics, and cosmetics. Contact lens materials have significantly evolved over time to minimize adverse effects associated with contact lens wearing, to maintain a regular corneal metabolism, and to preserve tear film stability. This article encompasses contact lens technology, including materials, chemical and physical properties, manufacturing processes, microbial contamination, and ocular complications. The function and the composition of the tear fluid are discussed to assess its potential as a diagnostic media. The regulatory standards of contact lens devices with regard to biocompatibility and contact lens market are presented. Future prospects in contact lens technology are evaluated, with particular interest given to theranostic applications for in situ continuous monitoring the ocular physiology.

show abstract

Wearable Bifocal Contact Lens for Continual Glucose Monitoring Integrated with Smartphone Readers

Elsherif

Alam

Salih

et al. 2021

Small

View full text Add to dashboard Cite

day. The CGM systems have revolutionized the way diabetes is managed, especially in type 1 diabetes. The first "professional" CGM system was approved by U.S Food and Drug Administration (FDA) in 1999. [2] The first non-invasive CGM, which allowed patients and providers to measure glucose concentration, was the "Glucowatch Biographer", which was approved by the FDA in 2001; however, this device has been withdrawn from the market due to low clinical efficacy and irreproducibility of measurements. [3] An advanced real-time CGM system (Guardian) was introduced by Medtronic in 2004. [4] In 2006, Dexcom released its first real-time CGM which is called the Short-Term Sensor (STS). [5] Free-Style Navigator by Abbott was released in 2008. [6] Dexcom introduced the G4 Platinum, G5, and G6 in 2012, 2015, and 2018, respectively, which allowed the glucose readings to be transmitted to the user's smartphone. [7] In 2016, Abbott released FreeStyle Libre Pro CGM which does not require frequent calibration and can be worn for 14 days. [8] In 2017, FreeStyle Libre, which could be worn for 10 days, with real-time user access was introduced. [9] However, the advances in CGM systems remained limited due to: i) they haven't been approved by the FDA for insulin dosing, and for use in hospitals and intensive care units, ii) high costs, iii) necessity for calibrations (at least twice a day) as a result of signal drift, and iv) regular replacement of the electrochemical sensor. [10] Commercial CGM systems detect glucose concentration in the interstitial fluid, which requires the insertion of the electrochemical probe through the skin. On the contrary, tears are easy and minimally-invasively accessed, and could be used as a blood proxy for diagnosing cancer, Alzheimer's disease, Parkinson's disease, cystic fibrosis, systemic sclerosis, aniridia, glaucoma, and dry eye. [11][12][13][14][15][16][17][18][19][20] In this context, contact lenses-integrated sensors that sample and measure tears offer a minimally-invasive diagnostic platform to detect numerous biomarkers. [21,22] The advances in electronics and microfabrication allowed for the miniaturization of the biosensors to fit in contact lenses without blocking the eye vision.The contact lenses have been integrated with electrochemical, light diffraction, and fluorescent glucose sensors. The electrochemical sensors are enzyme-based and they have been successfully attached to contact lenses comprising polyethylene terephthalate (PET), and polydimethylsiloxane (PDMS). [23][24][25][26][27] Commercial implantable continuous glucose monitoring devices are invasive and discomfort. Here, a minimally-invasive glucose detection system is developed to provide quantitative glucose measurements continually based on bifocal contact lenses. A glucose-sensitive phenylboronic acid derivative is immobilized in a hydrogel matrix and the surface of the hydrogel is imprinted with a Fresnel lens. The glucose-responsive hydrogel is attached to a commercial soft contact lens to be transformed into a bifocal conta...

show abstract

Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis

Cited by 14 publications

References 79 publications

Ophthalmological Manifestations and Tear Investigations in Systemic Sclerosis

Ophthalmological Manifestations and Tear Investigations in Systemic Sclerosis

Contact Lens Technology: From Fundamentals to Applications

Wearable Bifocal Contact Lens for Continual Glucose Monitoring Integrated with Smartphone Readers

Contact Info

Product

Resources

About